Government-Owned Inventions; Availability for Licensing, 61959 [2020-21709]

Download as PDF Federal Register / Vol. 85, No. 191 / Thursday, October 1, 2020 / Notices Intellectual Property: HHS Reference No. E–126–2020–0–US–01 ; U.S Patent Application 63/072,519 filed August 31, 2020. Licensing Contact: Brian W. Bailey, Ph.D.; 301–594–4094; bbailey@ mail.nih.gov. Dated: September 25, 2020. National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. Potential Commercial Applications Development of EMP2 inhibitor for treatment of neutrophil-dependent lung disorders, such as: [FR Doc. 2020–21710 Filed 9–30–20; 8:45 am] BILLING CODE 4140–01–P • • • • • DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by communicating with Vidita Choudhry, Ph.D., National Heart, Lung, and Blood, Office of Technology Transfer and Development, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–594– 4095; email: vidita.choudhry@nih.gov. A signed Confidential Disclosure Agreement may be required to receive any unpublished information. SUPPLEMENTARY INFORMATION: Technology description follows. jbell on DSKJLSW7X2PROD with NOTICES SUMMARY: Reducing Bloodstream Neutrophils as a Treatment for Lung Infection and Inflammation During lung infection, bloodstream neutrophils (PMNs) responding to infection travel to the airspace lumen. Although successful arrival of microbicidal PMNs to the airspace is essential for host defense against inhaled pathogens, excessive accumulation of PMNs in the lung contributes to the pathogenesis of several prevalent lung disorders, including acute lung injury, bronchiectasis, and chronic obstructive pulmonary disease (COPD). Unfortunately, there is no treatment for controlling PMN accumulation in the lung. The subject invention describes epithelial membrane protein 2 (EMP2) VerDate Sep<11>2014 22:13 Sep 30, 2020 Jkt 253001 as a lung epithelial protein that regulates PMN entry into the inflamed airspace. EMP2 knockout mice have reduced PMN accumulation and exhibit increased survival during bacterial infection. Inhibition of EMP2 can potentially reduce intra airway PMN accumulation and provide a specific treatment for various lung disorders. Acute lung injury pneumonia (bacterial, viral, fungal) bronchiectasis COPD and asthma radiation- or chemotherapeuticinduced pneumonitis • idiopathic or induced interstitial lung disease • bronchopulmonary dysplasia • lung transplant rejection Competitive Advantages • EMP2 can selectively target PMN accumulation in the lung, rather than broadly affecting PMN trafficking through all tissues. Development Stage • Early stage • In vitro and in vivo (animal) data available Inventors: Michael Brian Fessler (NIEHS), Carmen J. Williams (NIEHS), and Wan-Chi Lin (NIEHS). Intellectual Property: HHS Reference No. E–125–2018–0; U.S Provisional Patent Application 62/664,805 filed April 30, 2018, International Patent Application PCT/US2019/29801 filed on April 30, 2019. Publications: Lin WC, Gowdy KM, Madenspacher JH, et al. Epithelial membrane protein 2 governs transepithelial migration of neutrophils into the airspace. J Clin Invest. 2020;130(1):157–170. Licensing Contact: Vidita Choudhry, Ph.D.; 301–594–4095; vidita.choudhry@ nih.gov. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. Dated: September 28, 2020. Vidita Choudhry, Technology Development Specialist, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2020–21709 Filed 9–30–20; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 61959 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of an Exclusive Patent License: Allogeneic Therapy Using an Armored Payload and Chimeric Antigen Receptors Targeting GPC3 AGENCY: National Institutes of Health, HHS. ACTION: Notice. The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Senti Biosciences, Inc. (‘‘Senti’’) located in South San Francisco, CA. DATES: Only written comments and/or complete applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before October 16, 2020 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: David A Lambertson, Ph.D., Senior Technology Transfer Manager at Telephone at 240–276–5530 or Email at david.lambertson@nih.gov. SUPPLEMENTARY INFORMATION: SUMMARY: Intellectual Property The following represents the intellectual property to be licensed under the prospective agreement: (A) U.S. Provisional Patent Application 61/654,232 entitled ‘‘Highaffinity Monoclonal Antibodies To Glypican-3 And Use Thereof’’ [HHS Ref. E–136–2012–0–US–01], PCT Patent Application PCT/US2013/043633 entitled ‘‘High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof’’ [HHS Ref. E–136–2012–0– PCT–02], Chinese Patent 104520331 entitled ‘‘High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof’’ [HHS Ref. E–136–2012–0–CN– 03], Japanese Patent 6494507 entitled ‘‘High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof’’ [HHS Ref. E–136–2012–0–JP–04], South Korean Patent Application 10–2014– 7037046 entitled ‘‘High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof’’ [HHS Ref. E–136– 2012–0–KR–05], Singapore Patent 11201407972R entitled ‘‘High-affinity E:\FR\FM\01OCN1.SGM 01OCN1

Agencies

[Federal Register Volume 85, Number 191 (Thursday, October 1, 2020)]
[Notices]
[Page 61959]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-21709]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by communicating with Vidita Choudhry, Ph.D., National Heart, Lung, and 
Blood, Office of Technology Transfer and Development, 31 Center Drive, 
Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-594-4095; 
email: [email protected]. A signed Confidential Disclosure 
Agreement may be required to receive any unpublished information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Reducing Bloodstream Neutrophils as a Treatment for Lung Infection and 
Inflammation

    During lung infection, bloodstream neutrophils (PMNs) responding to 
infection travel to the airspace lumen. Although successful arrival of 
microbicidal PMNs to the airspace is essential for host defense against 
inhaled pathogens, excessive accumulation of PMNs in the lung 
contributes to the pathogenesis of several prevalent lung disorders, 
including acute lung injury, bronchiectasis, and chronic obstructive 
pulmonary disease (COPD). Unfortunately, there is no treatment for 
controlling PMN accumulation in the lung. The subject invention 
describes epithelial membrane protein 2 (EMP2) as a lung epithelial 
protein that regulates PMN entry into the inflamed airspace. EMP2 
knockout mice have reduced PMN accumulation and exhibit increased 
survival during bacterial infection. Inhibition of EMP2 can potentially 
reduce intra airway PMN accumulation and provide a specific treatment 
for various lung disorders.

Potential Commercial Applications

    Development of EMP2 inhibitor for treatment of neutrophil-dependent 
lung disorders, such as:

 Acute lung injury
 pneumonia (bacterial, viral, fungal)
 bronchiectasis
 COPD and asthma
 radiation- or chemotherapeutic-induced pneumonitis
 idiopathic or induced interstitial lung disease
 bronchopulmonary dysplasia
 lung transplant rejection

Competitive Advantages

 EMP2 can selectively target PMN accumulation in the lung, 
rather than broadly affecting PMN trafficking through all tissues.

Development Stage

 Early stage
 In vitro and in vivo (animal) data available

    Inventors: Michael Brian Fessler (NIEHS), Carmen J. Williams 
(NIEHS), and Wan-Chi Lin (NIEHS).
    Intellectual Property: HHS Reference No. E-125-2018-0; U.S 
Provisional Patent Application 62/664,805 filed April 30, 2018, 
International Patent Application PCT/US2019/29801 filed on April 30, 
2019.
    Publications: Lin WC, Gowdy KM, Madenspacher JH, et al. Epithelial 
membrane protein 2 governs transepithelial migration of neutrophils 
into the airspace. J Clin Invest. 2020;130(1):157-170.
    Licensing Contact: Vidita Choudhry, Ph.D.; 301-594-4095; 
[email protected]. This notice is made in accordance with 35 
U.S.C. 209 and 37 CFR part 404.

    Dated: September 28, 2020.
Vidita Choudhry,
Technology Development Specialist, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2020-21709 Filed 9-30-20; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.